close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

180 Life Sciences Corp. - Common Stock (NQ:ATNF)

7.040 UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about 180 Life Sciences Corp. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
180 Life Sciences Corp. Announces Closing of $3 Million Public Offering
From 180 Life Sciences Corp.
Via GlobeNewswire
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Releases Public Offering Pricing, Offering Could Reach $3M
Via Investor Brand Network
News headline image
180 Life Sciences Corp. Announces Pricing of $3 Million Public Offering
From 180 Life Sciences Corp.
Via GlobeNewswire
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Enters Agreement for Strategic PK Study
Via Investor Brand Network
Topics Derivatives
News headline image
180 Life Sciences Announces an Agreement for a Clinical Pharmacology Study Testing a New Formulation of CBD for Enhanced Oral Uptake
From 180 Life Sciences Corp.
Via GlobeNewswire
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Issues Update on Regulatory Approval Process for Dupuytren’s Disease Treatment
Via Investor Brand Network
News headline image
180 Life Sciences Provides Update on Regulatory Approval Process in the UK and US for Dupuytren’s Disease Treatment; Continues Consultations with the UK MHRA and Initiates a Type C Meeting Request With the US FDA
From 180 Life Sciences Corp.
Via GlobeNewswire
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces the Filing of a Provisional Patent Describing the Combination of CBD With GLP-1 Agonists to Suppress Appetite
Via Investor Brand Network
Topics Intellectual Property
News headline image
180 Life Sciences Corp. Announces the Filing of a Provisional Patent Describing the Combination of CBD With GLP-1 Agonists to Suppress Appetite
From 180 Life Sciences Corp.
Via GlobeNewswire
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Closes on $3M Registered Direct Offering, Concurrent Private Placement
Via Investor Brand Network
News headline image
180 Life Sciences Corp. Announces Closing of $3 Million Registered Direct Offering and Concurrent Private Placement
From 180 Life Sciences Corp.
Via GlobeNewswire
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces $3M Registered Direct, Concurrent Private Placement
Via Investor Brand Network
180 Life Sciences Corp. (NASDAQ: ATNF) Near the Top of Equities by Percentage Gain on 4/5
Via Investor Brand Network
Topics Derivatives
News headline image
180 Life Sciences Corp. Announces $3 Million Registered Direct Offering and Concurrent Private Placement
Priced At-The-Market Under Nasdaq Rules 
From 180 Life Sciences Corp.
Via GlobeNewswire
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) to Present at Summer Research Conference
Via Investor Brand Network
News headline image
180 Life Sciences Announces Presentation at the Gordon Conference
From 180 Life Sciences Corp.
Via GlobeNewswire
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Releases Update on Change of Status for Anti-TNF Frozen Shoulder Trial, Receives Patent Notification
Via Investor Brand Network
Topics Intellectual Property
News headline image
180 Life Sciences Announces Allowance of Claims for a US Patent for Dupuytren’s Disease Treatment and Application
From 180 Life Sciences Corp.
Via GlobeNewswire
News headline image
180 Life Sciences Provides Update Regarding Anti-TNF Frozen Shoulder Trial
From 180 Life Sciences Corp.
Via GlobeNewswire
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Medical Advisory Board Chair Coauthors Review of Early Stage Dupuytren’s Disease Treatment
Via Investor Brand Network
News headline image
180 Life Sciences Announces Publication of a Review on the Treatments for Early Stage Dupuytren’s Disease
From 180 Life Sciences Corp.
Via GlobeNewswire
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Engages Kinexum for Assistance in MAA Submission
Via Investor Brand Network
News headline image
180 Life Sciences Engages Kinexum for Assistance in Applying for Marketing Authorisation in the United Kingdom
From 180 Life Sciences Corp.
Via GlobeNewswire
News headline image
Newman Ferrara LLP Investigating Officers and Directors of 180 Life Sciences Corp. (ATNF)
From Newman Ferrara LLP
Via Business Wire
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Is Notified by NASDAQ Exchange of Full Compliance
Via Investor Brand Network
News headline image
180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
From 180 Life Sciences Corp.
Via GlobeNewswire
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces Review on Molecular Basis of Dupuytren’s Disease
Via Investor Brand Network
News headline image
180 Life Sciences Announces Publication of a Review on the Biological Basis of Dupuytren’s Disease
From 180 Life Sciences Corp.
Via GlobeNewswire
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Releases Shareholder Letter with Corporate Update
Via Investor Brand Network
News headline image
180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Shareholders
From 180 Life Sciences Corp.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today